Mechanical circulatory support in patients with cardiogenic shock not secondary to cardiotomy: a network meta-analysis.
Stefano BenenatiMatteo TomaClaudia CanaleRocco VergalloRoberta Della BonaDavide RicciMarco CanepaGabriele CrimiFrancesco SantiniPietro AmeriItalo PortoPublished in: Heart failure reviews (2021)
To compare the efficacy and safety of different mechanical circulatory support (MCS) devices in CS. A total of 24 studies (7 randomized controlled trials-RCTs-and 17 non-RCTs) involving 11,117 patients were entered in a Bayesian network meta-analysis. The primary endpoint was 30-day mortality. Secondary endpoints were stroke and bleeding (requiring transfusion and/or intracranial and/or fatal). Compared with no MCS, extra-corporeal membrane oxygenation (ECMO) reduced 30-day mortality when used both alone (OR 0.37, 95% CrI 0.15-0.90) and together with the micro-axial pump Impella (OR 0.13, 95% CrI 0.02-0.80) or intra-aortic balloon pump (IABP) (OR 0.19, 95% CrI 0.05-0.63), although the relevant articles were affected by significant publication bias. Consistent results were obtained in a sensitivity analysis including only studies of CS due to myocardial infarction. After halving the weight of studies with a non-RCT design, only the benefit of ECMO + IABP on 30-day mortality was maintained (OR 0.22, 95% CI 0.057-0.76). The risk of bleeding was increased by TandemHeart (OR 13, 95% CrI 3.50-59), Impella (OR 5, 95% CrI 1.60-18), and IABP (OR 2.2, 95% CrI 1.10-4.4). No significant differences were found across MCS strategies regarding stroke. Although limited by important quality issues, the studies performed so far indicate that ECMO, especially if combined with Impella or IABP, reduces short-term mortality in CS. MCS increases the hazard of bleeding.
Keyphrases
- extracorporeal membrane oxygenation
- atrial fibrillation
- case control
- acute respiratory distress syndrome
- cardiovascular events
- systematic review
- risk factors
- randomized controlled trial
- respiratory failure
- end stage renal disease
- ejection fraction
- clinical trial
- left ventricular
- heart failure
- body mass index
- prognostic factors
- type diabetes
- physical activity
- peritoneal dialysis
- cardiovascular disease
- left ventricular assist device
- meta analyses
- patient reported outcomes
- sickle cell disease
- patient reported
- aortic dissection